Kazia Therapeutics (KZIA) Intangibles (2013 - 2025)
Kazia Therapeutics' (KZIA) quarterly Intangibles came in at $713379.8 in Q4 2025, down 92.46% YoY from $9.5 million in Q4 2024, and up 2.52% on a QoQ basis from $695840.9 in Q2 2025.
Kazia Therapeutics (KZIA) Intangibles (2013 - 2025) Analysis & Trends
Kazia Therapeutics (KZIA) has 13 years of Intangibles data on file, last reported at $713379.8 in Q4 2025.
- Quarterly Intangibles fell 92.46% year-over-year to $713379.8 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $713379.8 (down 92.46% YoY) and the FY2025 annual result came in at $695840.9, down 93.14% from the prior year.
- Intangibles climbed to $713379.8 in Q4 2025, from $695840.9 in the prior quarter.
- In the past five years, Intangibles ranged from a high of $16.9 million in Q2 2021 to a low of $695840.9 in Q2 2025.
- A 5-year average of $10.1 million and a median of $11.1 million in 2023 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2021 — Intangibles soared 108.31% — and 2025, when it sank 93.14%.
- Tracing KZIA's Intangibles over 5 years: stood at $15.3 million in 2021, then retreated by 21.92% to $12.0 million in 2022, then declined by 11.09% to $10.6 million in 2023, then decreased by 11.04% to $9.5 million in 2024, then slumped by 92.46% to $713379.8 in 2025.
- The last three Intangibles figures came in at $713379.8 (Q4 2025), $695840.9 (Q2 2025), and $9.5 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Kazia Therapeutics | 4.22 Bn | 4.22 Bn | - | 713,379.83 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 713,379.83 |
| Jun 30, 2025 | 695,840.92 |
| Dec 31, 2024 | 9.46 Mn |
| Jun 30, 2024 | 10.15 Mn |
| Dec 31, 2023 | 10.63 Mn |
| Jun 30, 2023 | 11.54 Mn |
| Dec 31, 2022 | 11.96 Mn |
| Jun 30, 2022 | 13.71 Mn |
| Dec 31, 2021 | 15.32 Mn |
| Jun 30, 2021 | 16.94 Mn |
| Dec 31, 2020 | 8.67 Mn |
| Jun 30, 2020 | 8.13 Mn |
| Dec 31, 2019 | 8.85 Mn |
| Jun 30, 2019 | 9.45 Mn |
| Dec 31, 2018 | 10.07 Mn |
| Jun 30, 2018 | 11.04 Mn |
| Dec 31, 2017 | 192,188.12 |
| Jun 30, 2017 | 11.96 Mn |
| Dec 31, 2016 | 11.34 Mn |
| Jun 30, 2016 | 613,789.38 |